Abstract
Dopamine D3 receptor (D3R) on immune cells is involved in the pathogenesis of rheumatoid arthritis (RA). Mast cells (MCs) are currently identified as important effector cells in synovial inflammation of RA, but little is known about the role of D3R on synovial MCs in the pathogenesis of RA. Several inflammatory cells in the synovium induce reactive oxygen species (ROS) formation which are involved in the progression of RA. However, it is unclear whether D3R on synovial MCs is related to the levels of ROS in RA patients. In this study, a total of 73 patients with RA were divided into three groups according to disease activity DAS28 scores. The number of cases in group 1, group 2, and group 3 was 19, 26, and 28, respectively. We examined D3R-positive MC numbers in the synovial fluid and ROS levels in each group of RA patients, and we also analyzed the association of D3R-positive MC numbers with RA disease activity and ROS levels. MDA and protein carbonylation in the serum and synovial fluid were measured to reflect the level of lipid peroxidation and protein oxidation, respectively. Additionally, superoxide dismutase (SOD) and catalase (CAT) in the serum and synovial fluid were used to be markers of antioxidant levels. Our results showed that D3R-positive MCs in the synovial fluid showed a declining trend with the increased disease activity DAS28 score in RA patients. There was negative correlation between D3R-positive MC numbers in the synovial fluid and disease severity DAS28 score of RA patients. Moreover, D3R-positive MC numbers in the synovial fluid were negatively correlated with the level of MDA and protein carbonylation while were positively correlated with antioxidant levels such as SOD and CAT in RA patients. Our results suggested that D3R on MCs may be involved in ROS-mediated pathogenesis of RA.
Similar content being viewed by others
References
McInnes IB, O'Dell JR (2010) State-of-the-art: rheumatoid arthritis. Ann Rheum Dis 69(11):1898–1906. https://doi.org/10.1136/ard.2010.134684
Smolen JS, Aletaha D, McInnes IB (2016) Rheumatoid arthritis. Lancet 388(10055):2023–2038. https://doi.org/10.1016/S0140-6736(16)30173-8
Pitman N, Asquith DL, Murphy G, Liew FY, McInnes IB (2011) Collagen-induced arthritis is not impaired in mast cell-deficient mice. Ann Rheum Dis 70(6):1170–1171. https://doi.org/10.1136/ard.2010.134528
Pacheco R, Contreras F, Zouali M (2014) The dopaminergic system in autoimmune diseases. Front Immunol 5:117. https://doi.org/10.3389/fimmu.2014.00117
Lu JH, Liu YQ, Deng QW, Peng YP, Qiu YH (2015) Dopamine D2 receptor is involved in alleviation of type II collagen-induced arthritis in mice. Biomed Res Int 2015:496759. https://doi.org/10.1155/2015/496759
Nakano K, Yamaoka K, Hanami K, Saito K, Sasaguri Y, Yanagihara N, Tanaka S, Katsuki I, Matsushita S, Tanaka Y (2011) Dopamine induces IL-6-dependent IL-17 production via D1-like receptor on CD4 naive T cells and D1-like receptor antagonist SCH-23390 inhibits cartilage destruction in a human rheumatoid arthritis/SCID mouse chimera model. J Immunol 186(6):3745–3752. https://doi.org/10.4049/jimmunol.1002475
Wei L, Zhang C, Chen HY, Zhang ZJ, Ji ZF, Yue T, Dai XM, Zhu Q, Ma LL, He DY, Jiang LD (2015) Dopamine receptor DR2 expression in B cells is negatively correlated with disease activity in rheumatoid arthritis patients. Immunobiology 220(3):323–330. https://doi.org/10.1016/j.imbio.2014.10.016
Xu Y, Chen G (2015) Mast cell and autoimmune diseases. Mediat Inflamm 2015:246126–246128. https://doi.org/10.1155/2015/246126
Schubert N, Dudeck J, Liu P, Karutz A, Speier S, Maurer M, Tuckermann J, Dudeck A (2015) Mast cell promotion of T cell-driven antigen-induced arthritis despite being dispensable for antibody-induced arthritis in which T cells are bypassed. Arthritis Rheum 67(4):903–913. https://doi.org/10.1002/art.38996
Xue L, Li X, Ren HX, Wu F, Li M, Wang B, Chen FY, Cheng WY, Li JP, Chen YJ, Chen T (2015) The dopamine D3 receptor regulates the effects of methamphetamine on LPS-induced cytokine production in murine mast cells. Immunobiology 220(6):744–752. https://doi.org/10.1016/j.imbio.2014.12.021
Xue L, Geng Y, Li M, Jin YF, Ren HX, Li X, Wu F, Wang B, Cheng WY, Chen T, Chen YJ (2016) The effects of D3R on TLR4 signaling involved in the regulation of METH-mediated mast cells activation. Int Immunopharmacol 36:187–198. https://doi.org/10.1016/j.intimp.2016.04.030
Filippin LI, Vercelino R, Marroni NP, Xavier RM (2008) Redox signalling and the inflammatory response in rheumatoid arthritis. Clin Exp Immunol 152(3):415–422. https://doi.org/10.1111/j.1365-2249.2008.03634.x
Vasanthi P, Nalini G, Rajasekhar G (2009) Status of oxidative stress in rheumatoid arthritis. Int J Rheum Dis 12(1):29–33. https://doi.org/10.1111/j.1756-185X.2009.01375.x
Mateen S, Zafar A, Moin S, Khan AQ, Zubair S (2016) Understanding the role of cytokines in the pathogenesis of rheumatoid arthritis. Clin Chim Acta 455:161–171. https://doi.org/10.1016/j.cca.2016.02.010
Mateen S, Moin S, Khan AQ, Zafar A, Fatima N, Shahzad S (2017) Role of hydrotherapy in the amelioration of oxidant-antioxidant status in rheumatoid arthritis patients. Int J Rheum Dis. https://doi.org/10.1111/1756-185X.13118
Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31(3):315–324
Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38(1):44–48
Galli SJ, Nakae S, Tsai M (2005) Mast cells in the development of adaptive immune responses. Nat Immunol 6(2):135–142. https://doi.org/10.1038/ni1158
Abramson J, Pecht I (2007) Regulation of the mast cell response to the type 1 Fc epsilon receptor. Immunol Rev 217:231–254. https://doi.org/10.1111/j.1600-065X.2007.00518.x
Buege JA, Aust SD (1978) Microsomal lipid peroxidation. Methods Enzymol 52:302–310
Levine RL, Garland D, Oliver CN, Amici A, Climent I, Lenz AG, Ahn BW, Shaltiel S, Stadtman ER (1990) Determination of carbonyl content in oxidatively modified proteins. Methods Enzymol 186:464–478
Kono Y (1978) Generation of superoxide radical during autoxidation of hydroxylamine and an assay for superoxide dismutase. Arch Biochem Biophys 186(1):189–195
Aebi H (1984) Catalase in vitro. Methods Enzymol 105:121–126
Suurmond J, Dorjee AL, Boon MR, Knol EF, Huizinga TW, Toes RE, Schuerwegh AJ (2011) Mast cells are the main interleukin 17-positive cells in anticitrullinated protein antibody-positive and -negative rheumatoid arthritis and osteoarthritis synovium. Arthritis Res Ther 13(5):R150. https://doi.org/10.1186/ar3466
Reber LL, Frossard N (2014) Targeting mast cells in inflammatory diseases. Pharmacol Ther 142(3):416–435. https://doi.org/10.1016/j.pharmthera.2014.01.004
Lee DM, Friend DS, Gurish MF, Benoist C, Mathis D, Brenner MB (2002) Mast cells: a cellular link between autoantibodies and inflammatory arthritis. Science 297(5587):1689–1692. https://doi.org/10.1126/science.1073176
Feyerabend TB, Weiser A, Tietz A, Stassen M, Harris N, Kopf M, Radermacher P, Moller P, Benoist C, Mathis D, Fehling HJ, Rodewald HR (2011) Cre-mediated cell ablation contests mast cell contribution in models of antibody- and T cell-mediated autoimmunity. Immunity 35(5):832–844. https://doi.org/10.1016/j.immuni.2011.09.015
Eklund KK (2007) Mast cells in the pathogenesis of rheumatic diseases and as potential targets for anti-rheumatic therapy. Immunol Rev 217:38–52. https://doi.org/10.1111/j.1600-065X.2007.00504.x
McKenna F, McLaughlin PJ, Lewis BJ, Sibbring GC, Cummerson JA, Bowen-Jones D, Moots RJ (2002) Dopamine receptor expression on human T- and B-lymphocytes, monocytes, neutrophils, eosinophils and NK cells: a flow cytometric study. J Neuroimmunol 132(1–2):34–40
Arreola R, Alvarez-Herrera S, Perez-Sanchez G, Becerril-Villanueva E, Cruz-Fuentes C, Flores-Gutierrez EO, Garces-Alvarez ME, de la Cruz-Aguilera DL, Medina-Rivero E, Hurtado-Alvarado G, Quintero-Fabian S, Pavon L (2016) Immunomodulatory effects mediated by dopamine. J Immunol Res 2016:3160486. https://doi.org/10.1155/2016/3160486
Capellino S, Cosentino M, Wolff C, Schmidt M, Grifka J, Straub RH (2010) Catecholamine-producing cells in the synovial tissue during arthritis: modulation of sympathetic neurotransmitters as new therapeutic target. Ann Rheum Dis 69(10):1853–1860. https://doi.org/10.1136/ard.2009.119701
Nakashioya H, Nakano K, Watanabe N, Miyasaka N, Matsushita S, Kohsaka H (2011) Therapeutic effect of D1-like dopamine receptor antagonist on collagen-induced arthritis of mice. Mod Rheumatol 21(3):260–266. https://doi.org/10.1007/s10165-010-0387-2
Capellino S, Cosentino M, Luini A, Bombelli R, Lowin T, Cutolo M, Marino F, Straub RH (2014) Increased expression of dopamine receptors in synovial fibroblasts from patients with rheumatoid arthritis: inhibitory effects of dopamine on interleukin-8 and interleukin-6. Arthritis Rheum 66(10):2685–2693. https://doi.org/10.1002/art.38746
Datta S, Kundu S, Ghosh P, De S, Ghosh A, Chatterjee M (2014) Correlation of oxidant status with oxidative tissue damage in patients with rheumatoid arthritis. Clin Rheumatol 33(11):1557–1564. https://doi.org/10.1007/s10067-014-2597-z
Pham-Huy LA, He H, Pham-Huy C (2008) Free radicals, antioxidants in disease and health. Int J Biomed Sci 4(2):89–96
Khojah HM, Ahmed S, Abdel-Rahman MS, Hamza AB (2016) Reactive oxygen and nitrogen species in patients with rheumatoid arthritis as potential biomarkers for disease activity and the role of antioxidants. Free Radic Biol Med 97:285–291. https://doi.org/10.1016/j.freeradbiomed.2016.06.020
Kamanli A, Naziroglu M, Aydilek N, Hacievliyagil C (2004) Plasma lipid peroxidation and antioxidant levels in patients with rheumatoid arthritis. Cell Biochem Funct 22(1):53–57. https://doi.org/10.1002/cbf.1055
Lipinska J, Lipinska S, Stanczyk J, Sarniak A, Przyminska vel Prymont A, Kasielski M, Smolewska E (2015) Reactive oxygen species and serum antioxidant defense in juvenile idiopathic arthritis. Clin Rheumatol 34(3):451–456. https://doi.org/10.1007/s10067-014-2571-9
Kennedy A, Ng CT, Chang TC, Biniecka M, O'Sullivan JN, Heffernan E, Fearon U, Veale DJ (2011) Tumor necrosis factor blocking therapy alters joint inflammation and hypoxia. Arthritis Rheum 63(4):923–932. https://doi.org/10.1002/art.30221
Funding
This study was supported by grants from the Shaanxi Province Natural Science Fund (2017JQ8032), the Fundamental Research Funds for the Central Universities of China (no. xjj2016109 to Xue Li), and the Key Project of the Second Affiliated Hospital of Xi’an Jiaotong University (YJ(ZD)201614 to Xue Li).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Disclosures
None.
Ethical approval
All procedures performed in this study involving human participants were in accordance with the ethical standards of the Research Committee of Human Investigation of Medical College of Xi’an Jiaotong University. All participants gave informed consent.
Rights and permissions
About this article
Cite this article
Xue, L., Li, X., Chen, Q. et al. Associations between D3R expression in synovial mast cells and disease activity and oxidant status in patients with rheumatoid arthritis. Clin Rheumatol 37, 2621–2632 (2018). https://doi.org/10.1007/s10067-018-4168-1
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-018-4168-1